Corneal Crosslinking Reimbursement<br>In Its Tenth Year - Summary - MDSpire
Advertisement
Corneal Crosslinking Reimbursement<br>In Its Tenth Year
Providing crosslinking procedures in an ophthalmology practice is not for the faint of heart. Ultimately, despite its clinical importance, offering crosslinking remains financially challenging for many practices.
To explore the financial challenges and reimbursement landscape for corneal crosslinking procedures, particularly the epi-off and newly approved epi-on methods.
Key Findings:
Corneal crosslinking is crucial for treating progressive corneal ectasia but faces financial challenges, including administrative hurdles from Category III CPT code designation.
The epi-off procedure is widely covered, but reimbursement remains inadequate due to rising drug costs and variable payer policies.
The newer epi-on procedure lacks payer coverage due to its experimental status, limiting its adoption.
Limited reimbursement for the riboflavin drug Photrexa affects financial sustainability, with some payers providing inadequate coverage.
Interpretation:
Despite FDA approval and clinical importance, the financial viability of corneal crosslinking procedures is threatened by rising costs and inconsistent payer support, which may limit patient access to this essential treatment.
Limitations:
Inconsistent reimbursement policies across payers.
Limited coverage for the new epi-on procedure.
Financial strain from rising drug costs not matched by reimbursement, compounded by limited success with specialty pharmacies.
Conclusion:
Offering corneal crosslinking remains a significant challenge for practices due to financial constraints, and without improved payer support, access to this essential treatment may decline.
Cornea, cataract, refractive, and anterior segment surgery remain at the forefront of ophthalmic innovation, yet several challenges persist that demand critical reflection and collaborative solutions. As we navigate 2025, a few key issues warrant our attention.
